YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
Public ClinicalTrials.gov record NCT00048659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Study identification
- NCT ID
- NCT00048659
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- May 31, 2004
- Last update posted
- Jun 6, 2012
Ends 2004
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Clinical Research Center, LLC | Anchorage | Alaska | — | — |
| San Bernardino Urological Associates | San Bernardino | California | — | — |
| Western Clinical Research, Inc. | Torrance | California | — | — |
| Shands Hospital | Gainesville | Florida | — | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | — | — |
| Georgia Urology,PA Research Institute | Atlanta | Georgia | — | — |
| University of Chicago, Section of Hematology/Oncology | Chicago | Illinois | — | — |
| University of Illinois, Department of Urology | Chicago | Illinois | — | — |
| Michiana Hematology/Oncology | South Bend | Indiana | — | — |
| The Urologic Institute of New Orleans | Gretna | Louisiana | — | — |
| Henry Ford Hospital | Detroit | Michigan | — | — |
| Washington University School of Medicine | St Louis | Missouri | — | — |
| Memphis Cancer Center | Memphis | Tennessee | — | — |
| Virginia Mason Medical Center | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00048659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2012 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00048659 live on ClinicalTrials.gov.